UBS starts coverage of BioVersys with 'buy;' shares climb

BioVersys AG

20/03/2025 09:56

** Swiss biotech firm BioVersys BIOV.S shares up 4.3% at 36.20 Swiss francs

** UBS starts coverage with "buy" rating and PT of 48 francs, a 38.3% upside to the stock's last close

** Says the market does not fully reflect the "high probability of success" of the late stage trial data for co's lung infection drug BV100, due in H2 of 2027

** Estimates $430 mln in unadjusted peak sales for BV100, with a 70% probability of success

** If late-stage trial data shows superiority to Colistin, an antibiotic used to treat serious infections, and BIOV finds a strong partner, it could make up to $370 mln unadjusted peak sales just from China alone in RoW - brokerage

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))